Role of gremlin-1 in the pathophysiology of the adipose tissues.


Journal

Cytokine & growth factor reviews
ISSN: 1879-0305
Titre abrégé: Cytokine Growth Factor Rev
Pays: England
ID NLM: 9612306

Informations de publication

Date de publication:
02 2023
Historique:
received: 12 08 2022
accepted: 12 09 2022
pubmed: 27 9 2022
medline: 8 2 2023
entrez: 26 9 2022
Statut: ppublish

Résumé

Gremlin-1 is a secreted bone morphogenetic protein (BMP) antagonist playing a pivotal role in the regulation of tissue formation and embryonic development. Since its first identification in 1997, gremlin-1 has been shown to be a multifunctional factor involved in wound healing, inflammation, cancer and tissue fibrosis. Among others, the activity of gremlin-1 is mediated by its interaction with BMPs or with membrane receptors such as the vascular endothelial growth factor receptor 2 (VEGFR2) or heparan sulfate proteoglycans (HSPGs). Growing evidence has highlighted a central role of gremlin-1 in the homeostasis of the adipose tissue (AT). Of note, gremlin-1 is involved in AT dysfunction during type 2 diabetes, obesity and non-alcoholic fatty liver disease (NAFLD) metabolic disorders. In this review we discuss recent findings on gremlin-1 involvement in AT biology, with particular attention to its role in metabolic diseases, to highlight its potential as a prognostic marker and therapeutic target.

Identifiants

pubmed: 36155165
pii: S1359-6101(22)00074-0
doi: 10.1016/j.cytogfr.2022.09.004
pii:
doi:

Substances chimiques

Vascular Endothelial Growth Factor A 0
Bone Morphogenetic Proteins 0

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

51-60

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Auteurs

Elisabetta Grillo (E)

Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy. Electronic address: elisabetta.grillo@unibs.it.

Cosetta Ravelli (C)

Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.

Georgia Colleluori (G)

Department of Experimental and Clinical Medicine, Marche Polytechnic University, Via Tronto 10/A, 60020 Ancona, Italy.

Francesco D'Agostino (F)

Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.

Mattia Domenichini (M)

Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.

Antonio Giordano (A)

Department of Experimental and Clinical Medicine, Marche Polytechnic University, Via Tronto 10/A, 60020 Ancona, Italy.

Stefania Mitola (S)

Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH